EMAIL THIS PAGE TO A FRIEND

European journal of human genetics : EJHG

SMAD4 mutations causing Myhre syndrome result in disorganization of extracellular matrix improved by losartan.


PMID 24398790

Abstract

Myhre syndrome (MS, MIM 139210) is a connective tissue disorder that presents with short stature, short hands and feet, facial dysmorphic features, muscle hypertrophy, thickened skin, and deafness. Recurrent missense mutations in SMAD4 encoding for a transducer mediating transforming growth factor β (TGF-β) signaling are responsible for MS. We found that MS fibroblasts showed increased SMAD4 protein levels, impaired matrix deposition, and altered expression of genes encoding matrix metalloproteinases and related inhibitors. Increased TGF-β signaling and progression of aortic root dilation in Marfan syndrome can be prevented by the antihypertensive drug losartan, a TGF-β antagonists and angiotensin-II type 1 receptor blocker. Herein, we showed that losartan normalizes metalloproteinase and related inhibitor transcript levels and corrects the extracellular matrix deposition defect in fibroblasts from MS patients. The results of this study may pave the way toward therapeutic applications of losartan in MS.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4504207
Anti-phospho-Smad2 (pSer250) antibody produced in rabbit, affinity isolated antibody
SAB4300251
Anti-phospho-SMAD2 (pSer467) antibody produced in rabbit, affinity isolated antibody
SAB4300252
Anti-phospho-SMAD2 (pThr220) antibody produced in rabbit, affinity isolated antibody
SAB1412048
ANTI-SMAD4 antibody produced in mouse, clone 4C5, purified immunoglobulin, buffered aqueous solution
SAB1412049
ANTI-SMAD4 antibody produced in mouse, clone 4C6, purified immunoglobulin, buffered aqueous solution
SAB1412182
ANTI-SMAD4 antibody produced in mouse, clone 3D7, purified immunoglobulin, buffered aqueous solution
SAB1412494
ANTI-SMAD4 antibody produced in mouse, clone 4A6, purified immunoglobulin, buffered aqueous solution
SAB1412495
ANTI-SMAD4 antibody produced in mouse, clone 2G4, purified immunoglobulin, buffered aqueous solution
SAB1412496
ANTI-SMAD4 antibody produced in mouse, clone 3H1, purified immunoglobulin, buffered aqueous solution
SAB1412497
ANTI-SMAD4 antibody produced in mouse, clone 2C1, purified immunoglobulin, buffered aqueous solution
SAB1412498
ANTI-SMAD4 antibody produced in mouse, clone 4D12, purified immunoglobulin, buffered aqueous solution
SAB1412512
ANTI-SMAD4 antibody produced in mouse, clone 1A5, purified immunoglobulin, buffered aqueous solution
SAB1412596
ANTI-SMAD4 antibody produced in mouse, clone 1G9, purified immunoglobulin, buffered aqueous solution
SAB1412597
ANTI-SMAD4 antibody produced in mouse, clone 2E7, purified immunoglobulin, buffered aqueous solution
HPA019154
Anti-SMAD4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4200405
Anti-SMAD4 antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody
SAB2106277
Anti-SMAD4 antibody produced in rabbit, affinity isolated antibody
61188
Losartan potassium, analytical standard
C22H22ClKN6O
Y0001062
Losartan potassium, European Pharmacopoeia (EP) Reference Standard
C22H22ClKN6O
1370462
Losartan potassium, United States Pharmacopeia (USP) Reference Standard
C22H22ClKN6O
SAB1404038
Monoclonal Anti-SMAD4 antibody produced in mouse, clone 3E2, purified immunoglobulin, buffered aqueous solution
SAB5300375 Monoclonal Anti-SMAD4 antibody produced in mouse, clone 4G1C6, ascites fluid